These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23223314)

  • 1. Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
    Carroll RP; Hester J; Wood KJ; Harden PN
    Nephrol Dial Transplant; 2013 Feb; 28(2):462-5. PubMed ID: 23223314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effector Antitumor and Regulatory T Cell Responses Influence the Development of Nonmelanoma Skin Cancer in Kidney Transplant Patients.
    Crespo E; Fernandez L; Lúcia M; Melilli E; Lauzurica R; Penin RM; Quer A; Luque S; Quero M; Manonelles A; Torras J; Cruzado JM; Cañas L; Grinyó JM; Bestard O
    Transplantation; 2017 Sep; 101(9):2102-2110. PubMed ID: 28403126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion From Calcineurin Inhibitors to Mammalian Target of Rapamycin Inhibitors in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zeng J; Zhong Q; Feng X; Li L; Feng S; Fan Y; Song T; Huang Z; Wang X; Lin T
    Front Immunol; 2021; 12():663602. PubMed ID: 34539621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
    Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
    Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.
    van den Akker JM; Wetzels JF; Hoitsma AJ
    Kidney Int; 2006 Oct; 70(7):1355-7. PubMed ID: 16912706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
    Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
    Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
    [No Abstract]   [Full Text] [Related]  

  • 7. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
    Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
    Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients.
    Akimova T; Kamath BM; Goebel JW; Meyers KE; Rand EB; Hawkins A; Levine MH; Bucuvalas JC; Hancock WW
    Am J Transplant; 2012 Dec; 12(12):3449-61. PubMed ID: 22994804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.
    Kim KW; Chung BH; Kim BM; Cho ML; Yang CW
    Immunology; 2015 Jan; 144(1):68-78. PubMed ID: 24974886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of mTORI usage and outcomes in kidney transplant recipients.
    Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT
    Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mycophenolate-based Immunosuppressive Regimen Is Associated With Increased Mortality in Kidney Transplant Patients With COVID-19.
    Requião-Moura LR; Modelli de Andrade LG; de Sandes-Freitas TV; Cristelli MP; Viana LA; Nakamura MR; Garcia VD; Manfro RC; Simão DR; Almeida RAMB; Ferreira GF; Costa KMAH; de Lima PR; Pacheco-Silva A; Charpiot IMMF; Deboni LM; Ferreira TCA; Mazzali M; Calazans CAC; Oriá RB; Tedesco-Silva H; Medina-Pestana J;
    Transplantation; 2022 Oct; 106(10):e441-e451. PubMed ID: 35765133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
    Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
    Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune phenotype of peripheral blood cells and skin squamous cell carcinoma in organ transplant recipients.
    Dziunycz P; Hofbauer GF
    Expert Rev Clin Immunol; 2010 May; 6(3):359-62. PubMed ID: 20441422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
    Albano L; Alamartine E; Toupance O; Moulin B; Merville P; Rerolle JP; Tetaz R; Moal MC; Kamar N; Legendre C; Quéré S; Di Giambattista F; Terpereau A; Dantal J
    Ann Transplant; 2012; 17(1):58-67. PubMed ID: 22466910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.
    Lim WH; Eris J; Kanellis J; Pussell B; Wiid Z; Witcombe D; Russ GR
    Am J Transplant; 2014 Sep; 14(9):2106-19. PubMed ID: 25088685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis.
    Cervera C; Cofan F; Hernandez C; Soy D; Marcos MA; Sanclemente G; Bodro M; Moreno A; Diekmann F; Campistol JM; Oppenheimer F
    Transpl Int; 2016 Nov; 29(11):1216-1225. PubMed ID: 27564469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients on Diagnosis of Cancer.
    Peraldi MN; Berrou J; Venot M; Chardiny V; Durrbach A; Vieillard V; Debré P; Charron D; Suberbielle C; Chevret S; Glotz D; Dulphy N; Toubert A
    Transplantation; 2015 Nov; 99(11):2422-30. PubMed ID: 26798861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study.
    Fázio MR; Cristelli MP; Tomimori J; Koga CE; Ogawa MM; Beneventi GT; Tedesco-Silva H; Medina-Pestana J
    J Bras Nefrol; 2023; 45(4):480-487. PubMed ID: 37565728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.